As for possible nanotechnology-driven delivery, in vitro and in vivo studies were performed by Nikpoor and colleagues, who proposed two liposome formulations, one polyethylene glycol (PEG)ylated and the second non-PEGylated, containing anti-CTLA-4 blocking mAb in a C-26 colon cancer model [59]. This evidence concerns the gene CTLA4 and malignant colon neoplasm.